贝伐单抗用于治疗非小细胞肺癌的药物经济学研究

摘要/Abstract

摘要： 目的：综合评价贝伐单抗用于治疗非小细胞肺癌（NSCLC）的药物经济学研究，探讨贝伐单抗的临床疗效和成本效益。方法：从Pubmed、CNKI数据库检索有关贝伐单抗用于NSCLC治疗的药物经济学分析的中英文文献，综述评价结果。结果：纳入综述研究的11篇文献显示，在一线治疗中低剂量使用贝伐单抗联合双药化疗较单一化疗具有一定的成本-效果优势，在维持阶段、高剂量使用或与培美曲塞对照组相比，贝伐单抗的经济性优势并不明确。结论：贝伐单抗成本较高，国际研究结果尚不能适用于我国，需进一步开展基于我国数据的药物经济学评价。

Abstract: Objective： Literature review pharmacoeconomic analysis on patientsundergoing non-small cell cancer(NSClC) been treated with Bevacizumab， to explore efficacy and cost effectiveness of Bevacizumab（Bev）. Methods： We searched the Chinese and English literature of pharmacoeconomic analysis of Bevacizumab on Pubmed and CNKI database， and then reviewed pharmacoeconomic results of targeted drugs. Results： Among the eleven articles，compared with chemotherapy， Bev-containing regimen was reported to have cost-effectiveness in first line treatment with low dosage. But the cost-effectiveness of Bev-containing regimen is not clear in high dosage， for maintenance therapy and compared with pemetrexed/cisplatin.Conclusion：Bevacizumab is costly and the international results of the studys is not suitable for our country. Futher studys， comprehensive economic evaluation based on China date should be done.

戈颖莹,陈永法. 贝伐单抗用于治疗非小细胞肺癌的药物经济学研究[J]. .

GE Ying-ying and. Literature Review of Pharmacoeconomic on Bevacizumab in the Treatment of Non-small Cell Cancer(NSCLC)[J]. .

参考文献

[1] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015.[J]. Ca A Cancer Journal for Clinicians, 2016, 66(2):115.
[2] Crinò L, Weder W, Van Meerbeeck J, et al. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Annals of Oncology, 2010, 21 Suppl 5(suppl_5):v103.
[3] Mutlu H, Büyük?elik A, Aslan T, et al. The optimal chemotherapy timing in patients with inoperable locally advanced non small cell lung cancer.[J]. Medical Archives, 2013, 67(2):104.
[4] Zeng X, Karnon J, Wang S, et al. The Cost of Treating Advanced Non-Small Cell Lung Cancer: Estimates from the Chinese Experience[J]. Plos One, 2012, 7(10):e48323.
[5] Schiller J H, Harrington D, Belani C P, et al. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer[J]. New England Journal of Medicine, 2002, 346(2):92.
[6] 中华医学会呼吸病学分会肺癌学组, 中国肺癌防治联盟. 晚期非小细胞肺癌抗血管生成药物治疗中国呼吸领域专家共识(2016年版)[J]. 中华结核和呼吸杂志, 2016, 39(11):839-849.
[7] NCCN guidelines panel members. The NCCN guidelines for non-small cell lung cancer(version 4.2017).National Comprehensive Cancer Network.[2017-03-20].http://guide.medlive.cn/guideline/preview/1/12614?token=4c0405386400c0725323396211eabf1b
[8] 石远凯, 孙燕, 于金明,等. 中国晚期原发性肺癌诊治专家共识(2016年版)[J]. 中国肺癌杂志, 2016, 19(1):1-15.
[9] Peters S, Adjei A A, Gridelli C, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.[J]. Annals of Oncology, 2014, 25(suppl_3):iii27.
[10] Masters G A, Johnson D H, Temin S. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.[J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 2016, 33(30):3488-515.
[11] Sandler A, Gray R, Perry M C, et al. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer[J]. New England Journal of Medicine, 2006, 355(24):2542-50.
[12] Zhou C, Wu Y L, Chen G, et al. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer[J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 2015, 33(19):2197.
[13] Monk B J, Lammers P E, Cartwright T, et al. Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey[J]. Pharmaceuticals, 2017, 10(1).
[14]González G J, Gutiérrez N F, Nazco Casariego G J, et al. Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patients with advanced non-squamous non-small-cell lung cancer in Spain[J]. Farmacia Hospitalaria órgano Oficial De Expresión Científica De La Sociedad Espa?ola De Farmacia Hospitalaria, 2017, 41(n01):págs. 3-13.
[15] Kumar G, Woods B, Hess L M, et al. Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S[J]. Lung Cancer, 2015, 89(3):294.
[16] 干小红, 郭远新, 刁灏瑒. 标准一线化疗联用贝伐珠单抗在晚期非小细胞肺癌患者治疗中的成本-效果分析[J]. 中南药学, 2014(9):925-928.
[17] Shah M, Winfree K B, Peterson P, et al. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting ☆[J]. Lung Cancer, 2013, 82(1):121-127.
[18] Goulart B, Ramsey S. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer[J]. Value in Health the Journal of the International Society for Pharmacoeconomics Outcomes Research, 2011, 14(6):836.
[19] Ahn M J, Tsai C M, Hsia T C, et al. Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan[J]. Asia-Pacific journal of clinical oncology, 2011, 7 Suppl 2(s2):22.
[20] Bischoff HG, Heigener DF, Walzer S, Nuijten M. Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany. Lung Cancer. 2010;69 Suppl 1:S18–S23.
[21] Giuliani G, Grossi F, De M F, et al. Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy.[J]. Lung Cancer, 2010, 69 Suppl 1(Suppl 1):S11.
[22] Klein R, Wielage R, Muehlenbein C, et al. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer[J]. Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer, 2010, 5(8):1263.
[23] Stanisic S, Bischoff H G, Heigener D F, et al. Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC)[J]. Lung Cancer, 2010, 1(Suppl1):24-30.
[24] Klein R, Muehlenbein C, Liepa A M, et al. Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer[J]. Journal of Thoracic Oncology, 2009, 4(11):1404-1414.
[25] Reck M, Pawel J V, Zatloukal P, et al. Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL[J]. Journal of Clinical Oncology, 2009, 27(8):1227.
[26]胡彬彬, 陈宝清, 卢铀. 贝伐单抗治疗晚期非小细胞肺癌的疗效与安全性临床研究进展[J]. 中国肿瘤临床, 2017, 44(3).